Critical Care

, 19:P6 | Cite as

Heart rate variability in HIV-infected and AIDS

  • Gabriela AM Galdino
  • Fernanda R Moraes
  • Gesileny V Silva
  • Marilita F Accioly
Open Access
Poster presentation


Pearson Correlation Heart Rate Variability Supine Position Average Duration Dramatic Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


The availability of antiretroviral therapy (ART) has resulted in a dramatic reduction in HIV-associated mortality [1]. However, it is also known to induce an array of adverse effects [2, 3, 4], as autonomic dysfunction. The use of heart rate variability (HRV), allows the assessment of relative contribution of sympathetic and parasympathetic involvement [1].


The objective of this study was to assess the presence of autonomic dysfunction in HIV-infected and acquired immunodeficiency syndrome (AIDS) patients that receive ART. In order to do so, analysis of HRV was applied.


A total of 15 subjects with HIV and 34 with AIDS were analyzed. To capture HRV, the heart rate monitor Polar RS810CX was used. The HRV was recorded in a supine position for 20 minutes, and then while performing the respiratory sinus arrhythmia (RSA). The statistical analysis was calculated using ANOVA and Pearson correlation (α = 5%).


The HIV group had average duration of exposure to the virus of 4.5 ± 3.5 years, and the AIDS group 12.6 ± 6.6 years, both under ART. Only the %REC presented suggestive statistically significant difference (Table 1) of greater parasympathetic modulation in the AIDS group, while the RSA did not show a statistically significant difference (p >0.05).
Table 1

Time domain analysis.

HRV parameter (ms/%)





18.5 (11.5)

23.7 (17)



3.9 (6.8)

6.9 (9.9)



38.3 (11.2)

32.7 (6.7)


Data presented as mean (SD)


Based on chaos theory, %REC was more sensitive to identify lower parasympathetic modulation in the HIV group, probably due to shorter exposure to antiretroviral therapy. Therefore, it is suggested that the medication used by the population modifies the HRV.



Supported by FAPEMIG.


  1. 1.
    Lebech AM, Kristoffersen US, Mehlsen J, Wiinberg N, Petersen CL, Hesse B, et al: Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging. 2007, 27 (6): 363-367. 10.1111/j.1475-097X.2007.00760.x.CrossRefPubMedGoogle Scholar
  2. 2.
    Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998, 12 (7): F51-F58. 10.1097/00002030-199807000-00003.CrossRefPubMedGoogle Scholar
  3. 3.
    Dube MP, Sattler FR: Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998, 10 (6): 41-44.PubMedGoogle Scholar
  4. 4.
    Ramirez-Villegas JF, Lam-Espinosa E, Ramirez-Moreno DF, Calvo-Echeverry PC, AgredoRodriguez W: Heart rate variability dynamics for the prognosis of. cardiovascular risk. PLoS One. 2011, 6 (2): e17060-10.1371/journal.pone.0017060.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Galdino et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Gabriela AM Galdino
    • 1
  • Fernanda R Moraes
    • 1
  • Gesileny V Silva
    • 1
  • Marilita F Accioly
    • 1
  1. 1.Universidade Federal do Triângulo MineiroAbadia, UberabaBrazil

Personalised recommendations